Access to new and costly medicines

2025-02-19 · 2024/25:SoU14 p.2

The question is whether the government should commission a dedicated inquiry into the Swedish medicines system so patients gain quicker access to new and costly medicines, or whether the work already under way on cost-dampening measures, state subsidies and regulation should simply continue without such a dedicated review.

Committee proposal adopted, 148–21

VSMPCLKDMSD
YesNoAbstainAbsent

What each plan points to — and how the party voted

Plan → Vote

The plan is an AI reading of the party’s own manifesto and programme, with verbatim quotes. Not a prediction. Open the case → · airiksdagen.se